Global Nuclear Medicine Market Size study, by Type (Diagnostic, Therapeutic, Others), by Application (Neurology, Thyroid, Oncology), by Procedures, by End User, and Regional Forecasts 2022-2032

Description

The Global Nuclear Medicine Market is currently valued at approximately USD 5.5 billion in 2023 and is poised to exhibit a significant compound annual growth rate (CAGR) of 11.3% over the forecast period from 2024 to 2032. The burgeoning field of nuclear medicine, a critical segment within medical imaging and therapeutic technologies, is redefining diagnostic and treatment protocols. By utilizing radioactive isotopes, this technology provides unparalleled precision in detecting, monitoring, and treating complex conditions, such as cancers, neurological disorders, and thyroid abnormalities.

With advancements in technology, nuclear medicine is evolving rapidly, characterized by a shift towards hybrid imaging systems and targeted radiotherapies. Diagnostics, particularly Single Photon Emission Computed Tomography (SPECT) using Technetium and Positron Emission Tomography (PET) employing F-18 isotopes, have become essential tools in clinical decision-making. Therapeutics, leveraging beta and alpha emitters like Yttrium-90 and innovative brachytherapy solutions, are enhancing patient outcomes. These breakthroughs are augmented by substantial investment in research, bolstering the market's ability to cater to an array of medical challenges with heightened accuracy and efficacy.

The global market's growth trajectory is driven by rising incidences of chronic diseases, such as cancer and neurodegenerative disorders, necessitating advanced diagnostic and therapeutic interventions. Moreover, government initiatives and increased healthcare expenditure globally are catalyzing the adoption of nuclear medicine. However, the high cost of equipment and radioisotopes, coupled with stringent regulatory frameworks governing their use, remains a barrier to market expansion. Despite these challenges, innovations in isotopic production, coupled with collaborations between public and private sectors, present lucrative opportunities for stakeholders.

Regionally, North America dominates the nuclear medicine market, driven by advanced healthcare infrastructure, robust R&D activities, and a high prevalence of chronic diseases. Europe follows closely, benefiting from strong regulatory support and increasing investments in radiopharmaceutical development. The Asia-Pacific region, projected to witness the fastest growth, owes its momentum to rapidly improving healthcare facilities, a growing aging population, and rising awareness about nuclear medicine's therapeutic potential in countries such as India, China, and Japan.

Major market players included in this report are:

Siemens Healthineers
GE Healthcare
Cardinal Health
Bayer AG
Bracco Imaging S.p.A.
Curium Pharma
Advanced Accelerator Applications
Lantheus Holdings, Inc.
Jubilant Radiopharma
Nordion (Canada) Inc.
Isotopia Molecular Imaging Ltd.
Eckert & Ziegler Group
Alpha Tau Medical Ltd.
Theragnostics Ltd.
Telix Pharmaceuticals Limited

The detailed segments and sub-segment of the market are explained below:

By Type:

Diagnostic
- SPECT
Technetium
- PET
F-18
Therapeutic
- Beta Emitters
Y-90
- Alpha Emitters
- Brachytherapy

By Application:

Neurology
Thyroid
Oncology

By Procedures:

Imaging Procedures
Treatment Procedures

By End User:

Hospitals and Clinics
Academic and Research Institutes
Diagnostic Imaging Centers

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year: 2022
Base year: 2023
Forecast period: 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Nuclear Medicine Market Executive Summary 1.1. Global Nuclear Medicine Market Size & Forecast (2022-2032)

1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
- 1.3.3. By Procedures
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Nuclear Medicine Market Definition and Research Assumptions 2.1. Research Objective

2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Nuclear Medicine Market Dynamics 3.1. Market Drivers

3.1.1. Rising Incidence of Chronic Diseases
3.1.2. Advancements in Diagnostic and Therapeutic Technologies
3.1.3. Increased Healthcare Expenditure and Government Initiatives

3.2. Market Challenges
- 3.2.1. High Cost of Equipment and Radioisotopes
- 3.2.2. Stringent Regulatory Frameworks
3.3. Market Opportunities
- 3.3.1. Innovations in Isotopic Production
- 3.3.2. Collaborations Between Public and Private Sectors
- 3.3.3. Expansion in Emerging Markets

Chapter 4. Global Nuclear Medicine Market Industry Analysis 4.1. Porter's 5 Force Model

4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Nuclear Medicine Market Size & Forecasts by Type 2022-2032 5.1. Segment Dashboard

5.2. Global Nuclear Medicine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Diagnostic
  - 5.2.1.1. SPECT
  - 5.2.1.1.1. Technetium
  - 5.2.1.2. PET
  - 5.2.1.2.1. F-18
- 5.2.2. Therapeutic
  - 5.2.2.1. Beta Emitters
  - 5.2.2.1.1. Y-90
  - 5.2.2.2. Alpha Emitters
  - 5.2.2.3. Brachytherapy
- 5.2.3. Others

Chapter 6. Global Nuclear Medicine Market Size & Forecasts by Application 2022-2032 6.1. Segment Dashboard

6.2. Global Nuclear Medicine Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Neurology
- 6.2.2. Thyroid
- 6.2.3. Oncology
- 6.2.4. Others

Chapter 7. Global Nuclear Medicine Market Size & Forecasts by Procedures 2022-2032 7.1. Segment Dashboard

7.2. Global Nuclear Medicine Market: Procedures Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Imaging Procedures
- 7.2.2. Treatment Procedures
- 7.2.3. Others

Chapter 8. Global Nuclear Medicine Market Size & Forecasts by End User 2022-2032 8.1. Segment Dashboard

8.2. Global Nuclear Medicine Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Hospitals and Clinics
- 8.2.2. Academic and Research Institutes
- 8.2.3. Diagnostic Imaging Centers
- 8.2.4. Others

Chapter 9. Global Nuclear Medicine Market Size & Forecasts by Region 2022-2032 9.1. North America Nuclear Medicine Market

9.1.1. U.S. Nuclear Medicine Market
- 9.1.1.1. Diagnostic Breakdown Size & Forecasts, 2022-2032
- 9.1.1.2. Therapeutic Breakdown Size & Forecasts, 2022-2032
- 9.1.1.3. Others Breakdown Size & Forecasts, 2022-2032
- 9.1.1.4. End User Breakdown Size & Forecasts, 2022-2032
9.1.2. Canada Nuclear Medicine Market

9.2. Europe Nuclear Medicine Market
- 9.2.1. UK Nuclear Medicine Market
- 9.2.2. Germany Nuclear Medicine Market
- 9.2.3. France Nuclear Medicine Market
- 9.2.4. Spain Nuclear Medicine Market
- 9.2.5. Italy Nuclear Medicine Market
- 9.2.6. Rest of Europe Nuclear Medicine Market
9.3. Asia-Pacific Nuclear Medicine Market
- 9.3.1. China Nuclear Medicine Market
- 9.3.2. India Nuclear Medicine Market
- 9.3.3. Japan Nuclear Medicine Market
- 9.3.4. Australia Nuclear Medicine Market
- 9.3.5. South Korea Nuclear Medicine Market
- 9.3.6. Rest of Asia Pacific Nuclear Medicine Market
9.4. Latin America Nuclear Medicine Market
- 9.4.1. Brazil Nuclear Medicine Market
- 9.4.2. Mexico Nuclear Medicine Market
- 9.4.3. Rest of Latin America Nuclear Medicine Market
9.5. Middle East & Africa Nuclear Medicine Market
- 9.5.1. Saudi Arabia Nuclear Medicine Market
- 9.5.2. South Africa Nuclear Medicine Market
- 9.5.3. Rest of Middle East & Africa Nuclear Medicine Market

Chapter 10. Competitive Intelligence 10.1. Key Company SWOT Analysis

10.1.1. Siemens Healthineers
10.1.2. GE Healthcare
10.1.3. Cardinal Health

10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Siemens Healthineers
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. GE Healthcare
- 10.3.3. Cardinal Health
- 10.3.4. Bayer AG
- 10.3.5. Bracco Imaging S.p.A.
- 10.3.6. Curium Pharma
- 10.3.7. Advanced Accelerator Applications
- 10.3.8. Lantheus Holdings, Inc.
- 10.3.9. Jubilant Radiopharma
- 10.3.10. Nordion (Canada) Inc.
- 10.3.11. Isotopia Molecular Imaging Ltd.
- 10.3.12. Eckert & Ziegler Group
- 10.3.13. Alpha Tau Medical Ltd.
- 10.3.14. Theragnostics Ltd.
- 10.3.15. Telix Pharmaceuticals Limited

Chapter 11. Research Process 11.1. Research Process

11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing

11.2. Research Attributes